Aggregated price index with volume information
Summary:
- Pharmaceuticals: Major stocks down 1.0% on average while median return down 0.8% in a day
- Pharmaceuticals: Major stocks up 3.6% on average while median return up 1.4% in a week
- Pharmaceuticals: Major stocks up 3.6% on average while median return up 5.2% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $CRVS 62.4%, $HROW 54.5%, $CVAC 43.0%, $ASRT 42.7%, $PAHC 41.1%
- 1M losers are : Losers for past month are $YMAB -22.7%, $ALRN -24.6%, $AQST -30.9%, $EYPT -32.3%, $LYRA -92.9%
- 1W winners are : Winners for past week are $HROW 44.5%, $ANVS 40.1%, $ACIU 37.7%, $IKT 32.1%, $CKPT 25.3%
- 1W losers are : Losers for past week are $PRAX -6.9%, $HCM -7.3%, $EPIX -8.7%, $ANNX -8.8%, $LUMO -13.0%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 8.5%, for the past 3 months is 8.9%
In the past month for a 5 days rolling window, the highest corrrelation is 17.8%, the lowest correlation is 1.9%, the latest correlation is 6.6%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 73.4% between AKRO and ASRT
The lowest correlation is -69.5% between AZN and BMY
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, lead
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024. Investors participating in the Benchmark conference can request a meeti
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Could Amgen be the next stock to soar due to a GLP-1 drug?
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences. Praxis management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conferenc